Fort Point Capital Partners’s Stoke Therapeutics STOK Stock Holding History

Fort Point Capital Partners’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,429	Closed	-$1.77M	–	233
2025 Q3	$1.77M	Sell	75,429 -5	-0%	-$86	0.21%	77
2025 Q2	$856K	Buy	75,434 +5	+0%	+$47	0.06%	165
2025 Q1	$502K	Hold	75,429	–	–	0.06%	204
2024 Q4	$832K	Hold	75,429	–	–	0.09%	148
2024 Q3	$927K	Hold	75,429	–	–	0.11%	122
2024 Q2	$1.02M	Hold	75,429	–	–	0.13%	115
2024 Q1	$1.02M	Hold	75,429	–	–	0.14%	119
2023 Q4	$397K	Hold	75,429	–	–	0.06%	204
2023 Q3	$297K	Hold	75,429	–	–	0.05%	211
2023 Q2	$802K	Hold	75,429	–	–	0.11%	113
2023 Q1	$628K	Hold	75,429	–	–	0.1%	141
2022 Q4	$696K	Sell	75,429 -60,610	-45%	-$630K	0.11%	126
2022 Q3	$1.75M	Sell	136,039 -23,961	-15%	-$382K	0.29%	68
2022 Q2	$2.11M	Hold	160,000	–	–	0.35%	60
2022 Q1	$3.37M	Hold	160,000	–	–	0.47%	51
2021 Q4	$3.84M	Buy	+160,000	New	+$3.82M	0.52%	47

Other funds holding STOK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fort Point Capital Partners's STOK Position: Q4 2025 in Review

Fort Point Capital Partners sold out of Stoke Therapeutics (STOK) in Q4 2025, closing a stake of 75,429 shares — an estimated $1.77M sold.

Fort Point Capital Partners first reported a position in STOK in Q4 2021 and held it in 16 quarters. The position peaked at $3.84M in Q4 2021. 183 funds tracked by Wall St. Rank hold STOK as of Q4 2025.

Fort Point Capital Partners reported no remaining Stoke Therapeutics position as of Q4 2025 after selling out during the quarter.
Fort Point Capital Partners sold 75,429 Stoke Therapeutics shares in Q4 2025, an estimated $1.77M.
Fort Point Capital Partners first reported a position in Stoke Therapeutics in Q4 2021 and held it in 16 quarters.
Fort Point Capital Partners's Stoke Therapeutics position peaked at $3.84M in Q4 2021.
183 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2025.

Based on Fort Point Capital Partners's 13F filing for Q4 2025, filed 13 Feb 2026.